Our findings suggest that targeting miR-155 or other factors involved in regulating CTLA4 expression in Treg cells, without affecting T cells, could be a potential strategy to improve the efficacy of immunotherapy in melanoma. This evidence concerns the gene CTLA4 and melanoma.